Question · Q4 2025
Evie Tsai, on behalf of Gavin, asked for color on enrollment trends for the Panorama and Ascend trials, given the Voyage data timeline. She also inquired about additional factors, beyond the sample size re-estimation and variability, that are contributing to Definium's incremental confidence in the program.
Answer
Robert Barrow, CEO, highlighted rapid enrollment for Emerge, strong progress for Voyage (80% complete), and anticipated updates for Panorama at the Analyst Day. He noted accelerated DEA approvals for Ascend. Mr. Barrow reiterated high confidence in DT120's profile, citing the Voyage interim analysis implying over 99% power and a low statistical significance threshold, without commenting on specific variables.
Ask follow-up questions
Fintool can predict 
DFTX's earnings beat/miss a week before the call